Key facts
- Dillico’s last known valuation is $23.3M (Jul 2025).
- It has raised $8.8M; the latest was Early Stage VC ($8.7M) in Jul 2025.
- Notable investors include Bpifrance, UI Investissement, Angelor, Deepbright Ventures, Deeperly (Belgium) — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Dillico
- ·The full record, as it builds
Funding rounds
No funding rounds for Dillico are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dillico
Operator of an mRNA manufacturing technology company intended to revolutionize global healthcare access through scalable, automated production of vaccines and therapeutics. The company offers All-ScaleFlow-based equipment and manufacturing infrastructure that enables continuous, digitalized and flexible production of mRNA-LNP therapies, enabling customers to manufacture millions of doses annually with minimal footprint and maximum efficiency.
- Sector
- Healthcare
- HQ
- Meylan, France
- Founded
- 2022
- Employees
- 9
- Website
- dillico.com/
- Ownership
- Privately Held (backing)
Dillico doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dillico shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dillico in its N-PORT filings yet. We sweep new filings monthly.